Cerecor (CERC) Stock Price, News & Analysis

Company Overview

Cerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.

Key Stats

• Today's Range: $4.91 to $5.02
• 50-Day Range: $2.06 to $3.24
• 52-Week Range: $1.98 to $4.50
• Volume: 22,006 shs
• Average Volume: 1.27 million shs
• Market Capitalization: $476.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CERC Stock Analysis - Frequently Asked Questions

How were Cerecor's earnings last quarter?

Cerecor Inc. (NASDAQ:CERC) announced its earnings results on Sunday, August, 1st. The company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.01. The business earned $3.36 million during the quarter. Cerecor had a negative net margin of 1,194.82% and a negative trailing twelve-month return on equity of 261.82%.

What other stocks do shareholders of Cerecor own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cerecor investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), OPKO Health (OPK), VBI Vaccines (VBIV), Pfizer (PFE) and Agile Therapeutics (AGRX).

Company Calendar

• Last Earnings: 8/01/2021
• Today: 7/04/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CERC
• CIK: 1534120
• Web: www.cerecor.com
• Phone: (410) 522-8707
• Fax: N/A
• Employees: 31
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.57)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$63.50 million
• Net Margins: -1,194.82%
• Pretax Margin: N/A
• Return on Equity: -261.82%
• Return on Assets: -133.96%

Debt

• Debt-to-Equity Ratio: 0.79
• Current Ratio: 2.19
• Quick Ratio: 2.18

Sales & Book Value

• Annual Sales: $6.70 million
• Price / Sales: 71.08
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.22 per share
• Price / Book: 22.55

Miscellaneous

• Outstanding Shares: 96,009,000
• Free Float: N/A
• Market Cap: $476.20 million
• Optionable: Not Optionable
• Beta: 1.44